{"product_id":"jnj-vrio-analysis","title":"Johnson \u0026 Johnson (JNJ): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis of Johnson \u0026amp; Johnson gives you a clear, research-based view of how the company turns trust, patents, regulatory execution, \u003cstrong\u003e132\u003c\/strong\u003e factories, AI, cash strength, and global customer relationships into sustained competitive advantage as of \u003cstrong\u003eJune 2026\u003c\/strong\u003e. You’ll learn how each resource creates value, why it is hard to copy, and how the company is organized to turn those strengths into performance in medicines and MedTech.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Global brand trust and Credo reputation\u003c\/h2\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s trust base supports physician, patient, payer, and investor confidence. It also helps with pricing, adoption, and litigation resilience.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFounded in \u003cstrong\u003e1886\u003c\/strong\u003e, Johnson \u0026amp; Johnson has a long operating record that makes trust financially useful. Its \u003cstrong\u003e2024\u003c\/strong\u003e net sales were \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e, showing that this reputation supports large-scale commercial performance.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe Johnson \u0026amp; Johnson Credo dates to \u003cstrong\u003e1943\u003c\/strong\u003e. Few healthcare companies have a comparable combination of \u003cstrong\u003e1886\u003c\/strong\u003e heritage and a formal, long-standing trust statement.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThis is difficult to copy because a rival cannot quickly recreate an \u003cstrong\u003e1886\u003c\/strong\u003e founding base or a \u003cstrong\u003e1943\u003c\/strong\u003e Credo backed by decades of visible execution.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is organized to use this asset through \u003cstrong\u003e2\u003c\/strong\u003e reportable segments and global commercialization. The scale of \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e net sales shows that the company turns trust into operating results.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO test\u003c\/td\u003e\n    \u003ctd\u003eReal-life data\u003c\/td\u003e\n    \u003ctd\u003eStrategic effect\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e1886\u003c\/strong\u003e; \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eSupports confidence and commercial scale\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1943\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCredo-based trust is uncommon in healthcare\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e1886\u003c\/strong\u003e; \u003cstrong\u003e1943\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eHistory and reputation are not quickly copied\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e; \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eCommercial structure supports trust at scale\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1886\u003c\/strong\u003e founding year.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1943\u003c\/strong\u003e Credo date.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e reportable segments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e 2024 net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained competitive advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Patent portfolio and late-stage pipeline in Innovative Medicine\u003c\/h2\u003e\n\u003cp\u003eInnovative Medicine generated \u003cstrong\u003e$57.1B\u003c\/strong\u003e of 2024 sales out of \u003cstrong\u003e$88.8B\u003c\/strong\u003e total company sales, or \u003cstrong\u003e64.3%\u003c\/strong\u003e. Johnson \u0026amp; Johnson spent \u003cstrong\u003e$17.2B\u003c\/strong\u003e on R\u0026amp;D in 2024, equal to \u003cstrong\u003e19.4%\u003c\/strong\u003e of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e Innovative Medicine sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$88.8B\u003c\/strong\u003e total company sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e R\u0026amp;D expense in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO item\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eAnalysis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e; \u003cstrong\u003e64.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePatent-backed medicines drive most of company sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e; \u003cstrong\u003e$17.2B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eA high-sales, patent-supported medicine base at this scale is rare.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e; \u003cstrong\u003e19.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYears of R\u0026amp;D spending and clinical development are costly to copy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e; \u003cstrong\u003e$88.8B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCapital is available to fund IP defense and late-stage programs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e; \u003cstrong\u003e64.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports sustained competitive advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe patent portfolio matters because it supports \u003cstrong\u003e$57.1B\u003c\/strong\u003e of revenue in oncology, immunology, neuroscience, and infectious disease.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe combination of approved assets and late-stage candidates behind \u003cstrong\u003e$57.1B\u003c\/strong\u003e in annual sales is rare.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is hard to copy because Johnson \u0026amp; Johnson invested \u003cstrong\u003e$17.2B\u003c\/strong\u003e in R\u0026amp;D in 2024.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is organized to use this asset base through a \u003cstrong\u003e$88.8B\u003c\/strong\u003e sales platform and ongoing R\u0026amp;D funding.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThis supports sustained competitive advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Regulatory, clinical, and launch execution engine\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson reported \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 sales, with operations across \u003cstrong\u003e2\u003c\/strong\u003e segments and a footprint in \u003cstrong\u003e175\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA regulatory, clinical, and launch system at this scale is uncommon. Johnson \u0026amp; Johnson was founded in \u003cstrong\u003e1886\u003c\/strong\u003e, giving it \u003cstrong\u003e138\u003c\/strong\u003e years of operating history in 2024.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e175\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounding year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1886\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating history in 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e138 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating this capability requires the same long-run data, filings, trial infrastructure, and launch experience built over \u003cstrong\u003e138\u003c\/strong\u003e years.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is structured around \u003cstrong\u003e2\u003c\/strong\u003e segments and a \u003cstrong\u003e175\u003c\/strong\u003e-country footprint, which supports integrated development, medical, legal, and commercial execution.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained competitive advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e175\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1886\u003c\/strong\u003e founding year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e138\u003c\/strong\u003e years of operating history in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Global manufacturing and supply-chain resilience\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e132\u003c\/strong\u003e manufacturing sites and a \u003cstrong\u003e$55 billion\u003c\/strong\u003e U.S. investment over \u003cstrong\u003e4\u003c\/strong\u003e years make the network valuable, hard to copy, and well organized.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e132\u003c\/strong\u003e factories support supply continuity, risk reduction, and faster launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$55 billion\u003c\/strong\u003e U.S. investment over \u003cstrong\u003e4\u003c\/strong\u003e years\u003c\/li\u003e\n\u003cli\u003eProducts sold in more than \u003cstrong\u003e175\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e132\u003c\/strong\u003e manufacturing sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO item\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eBusiness impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e132\u003c\/strong\u003e sites\u003c\/td\u003e\n\u003ctd\u003eSupply continuity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. investment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$55 billion\u003c\/strong\u003e over \u003cstrong\u003e4\u003c\/strong\u003e years\u003c\/td\u003e\n\u003ctd\u003eCapacity and localization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal reach\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e175\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eLaunch and distribution scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eCombining scale, quality, localization, and automation across \u003cstrong\u003e132\u003c\/strong\u003e factories is rare.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating \u003cstrong\u003e132\u003c\/strong\u003e sites and a \u003cstrong\u003e$55 billion\u003c\/strong\u003e capital plan is capital intensive and slow.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eTechnical operations leadership, AI monitoring, and the \u003cstrong\u003e$55 billion\u003c\/strong\u003e U.S. investment support execution.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained competitive advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: MedTech innovation, robotics, and platform ecosystems\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e 2024 sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.1B\u003c\/strong\u003e Shockwave Medical acquisition value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$16.6B\u003c\/strong\u003e Abiomed acquisition value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e named platforms: Shockwave, Abiomed, OTTAVA, VARIPULSE, Ethicon.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e5\u003c\/strong\u003e platform names across surgery, electrophysiology, cardiovascular, and hospital products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.1B\u003c\/strong\u003e and \u003cstrong\u003e$16.6B\u003c\/strong\u003e platform deals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major acquisitions in the portfolio data above.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e large acquisitions, clinical evidence, engineering depth, and installed-base effects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$13.1B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$16.6B\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003ePlatform strategy, branding, and tuck-in M\u0026amp;A.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eJohnson \u0026amp; Johnson\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave Medical\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSustained competitive advantage\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Data, AI, and digital operating capabilities\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e in 2023 sales and \u003cstrong\u003e$15.1 billion\u003c\/strong\u003e in 2023 research and development spending show why data, AI, and digital operating capabilities matter across Johnson \u0026amp; Johnson’s \u003cstrong\u003e2\u003c\/strong\u003e operating segments.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e of 2023 sales and \u003cstrong\u003e$15.1 billion\u003c\/strong\u003e of R\u0026amp;D spending support drug discovery, trial work, manufacturing, and commercial execution.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eIntegrated use across \u003cstrong\u003e2\u003c\/strong\u003e major segments is uncommon at this scale.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe model is harder to copy because the scale is \u003cstrong\u003e$85.2 billion\u003c\/strong\u003e in sales, with R\u0026amp;D at \u003cstrong\u003e$15.1 billion\u003c\/strong\u003e and operations spread across \u003cstrong\u003e2\u003c\/strong\u003e segments.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eEnterprise-scale execution is supported by \u003cstrong\u003e2\u003c\/strong\u003e segments and annual R\u0026amp;D investment of \u003cstrong\u003e$15.1 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO\u003c\/th\u003e\n    \u003cth\u003eReal-life number\u003c\/th\u003e\n    \u003cth\u003eNumeric read\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e2023 sales base\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$15.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e2023 R\u0026amp;D base\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eOperating segments\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e and \u003cstrong\u003e$15.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eScale and spend make copying harder\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSegments for deployment and control\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e sales\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$15.1 billion\u003c\/strong\u003e R\u0026amp;D\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Financial strength and capital allocation capacity\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e 2024 net sales, \u003cstrong\u003e$17.2B\u003c\/strong\u003e 2024 R\u0026amp;D expense, and \u003cstrong\u003e$1.30\u003c\/strong\u003e quarterly dividend per share in 2025, or \u003cstrong\u003e$5.20\u003c\/strong\u003e annualized.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO item\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e2024 R\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eCredit ratings\u003c\/td\u003e\n\u003ctd\u003eAAA \/ Aaa \/ AAA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e2025 quarterly dividend per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.30\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e2025 annualized dividend per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.20\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficiency\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D as a share of 2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e2024 net sales to 2024 R\u0026amp;D ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.2x\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$17.2B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAAA \/ Aaa \/ AAA\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e5.2x\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$17.2B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$1.30\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$5.20\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained competitive advantage: \u003cstrong\u003e$88.8B\u003c\/strong\u003e, \u003cstrong\u003e$17.2B\u003c\/strong\u003e, \u003cstrong\u003e$1.30\u003c\/strong\u003e, \u003cstrong\u003e$5.20\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Global commercial reach and customer relationships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e 2024 net sales were \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e, and 2024 R\u0026amp;D expense was \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Johnson \u0026amp; Johnson had \u003cstrong\u003e138,100\u003c\/strong\u003e employees worldwide and \u003cstrong\u003e2\u003c\/strong\u003e reportable segments in 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eStrategic meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHospital, surgeon, oncologist, and payer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e2024 R\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical evidence base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eWorldwide employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e138,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGlobal customer coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eReportable segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExecution structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Deep customer relationships built across \u003cstrong\u003e138,100\u003c\/strong\u003e employees and supported by \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e in R\u0026amp;D are difficult to copy quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003e2\u003c\/strong\u003e reportable segments support commercial execution.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e sustained competitive advantage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - VRIO Analysis: Specialized talent, leadership, and Credo-driven culture\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 sales and a \u003cstrong\u003e2023\u003c\/strong\u003e consumer health separation make leadership depth a real operating asset. The Credo, first written in \u003cstrong\u003e1943\u003c\/strong\u003e, gives the culture \u003cstrong\u003e4\u003c\/strong\u003e stakeholder duties: customers, employees, communities, and stockholders.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eSpecialized scientists, engineers, regulatory leaders, and device managers help Johnson \u0026amp; Johnson run \u003cstrong\u003e2\u003c\/strong\u003e operating segments in \u003cstrong\u003e2024\u003c\/strong\u003e and absorb large-scale change after the \u003cstrong\u003e2023\u003c\/strong\u003e separation.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe combination of senior leadership experience and a \u003cstrong\u003e1943\u003c\/strong\u003e Credo is rare. The culture has had \u003cstrong\u003e81\u003c\/strong\u003e years to shape decision-making by \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can hire talent, but they cannot quickly copy \u003cstrong\u003e81\u003c\/strong\u003e years of institutional knowledge, the \u003cstrong\u003e1\u003c\/strong\u003e Credo, or the accumulated judgment that comes from repeated reorganizations.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is organized around \u003cstrong\u003e2\u003c\/strong\u003e major businesses, with leadership and succession systems built to support execution across a company that generated \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e of sales in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eCompetitive effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003eFunds specialist talent and large-scale execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1943\u003c\/strong\u003e, \u003cstrong\u003e4\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCredo first written; 4 stakeholder groups\u003c\/td\u003e\n\u003ctd\u003eCulture is uncommon and hard to match\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e81\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYears from 1943 to 2024\u003c\/td\u003e\n\u003ctd\u003eInstitutional knowledge builds over decades\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e, \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTwo operating segments after the 2023 separation\u003c\/td\u003e\n\u003ctd\u003eTalent is aligned to the current structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCredo plus specialized leadership\u003c\/td\u003e\n\u003ctd\u003eHard to copy and durable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1943\u003c\/strong\u003e: Credo first written.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e: stakeholder groups in the Credo.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e: consumer health separation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e: operating segments in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e81\u003c\/strong\u003e: years of Credo-based culture by \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516191989909,"sku":"jnj-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/jnj-vrio-analysis.png?v=1740187367","url":"https:\/\/dcf-model.com\/pt\/products\/jnj-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}